BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23856341)

  • 21. Opposite effects of interferon-β on new B and T cell release from production sites in multiple sclerosis patients.
    Zanotti C; Chiarini M; Serana F; Capra R; Rottoli M; Rovaris M; Cavaletti G; Clerici R; Rezzonico M; Caimi L; Imberti L
    J Neuroimmunol; 2011 Dec; 240-241():147-50. PubMed ID: 22078237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B cells undergo unique compartmentalized redistribution in multiple sclerosis.
    Haas J; Bekeredjian-Ding I; Milkova M; Balint B; Schwarz A; Korporal M; Jarius S; Fritz B; Lorenz HM; Wildemann B
    J Autoimmun; 2011 Dec; 37(4):289-99. PubMed ID: 21924866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis.
    Kashani N; Kelland EE; Vajdi B; Anderson LM; Gilmore W; Lund BT
    Front Immunol; 2021; 12():706278. PubMed ID: 34777337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity.
    Ireland SJ; Blazek M; Harp CT; Greenberg B; Frohman EM; Davis LS; Monson NL
    Autoimmunity; 2012 Aug; 45(5):400-14. PubMed ID: 22432732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thymic output and peripheral T lymphocyte subsets in relapsing--remitting multiple sclerosis patients treated or not by IFN-beta.
    Puissant-Lubrano B; Viala F; Winterton P; Abbal M; Clanet M; Blancher A
    J Neuroimmunol; 2008 Jan; 193(1-2):188-94. PubMed ID: 18068811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms.
    Duszczyszyn DA; Beck JD; Antel J; Bar-Or A; Lapierre Y; Gadag V; Haegert DG
    Clin Exp Immunol; 2006 Feb; 143(2):305-13. PubMed ID: 16412055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes.
    Comabella M; Cantó E; Nurtdinov R; Río J; Villar LM; Picón C; Castilló J; Fissolo N; Aymerich X; Auger C; Rovira A; Montalban X
    Hum Mol Genet; 2016 Jan; 25(2):308-16. PubMed ID: 26604134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-15a and 16-1 are downregulated in CD4+ T cells of multiple sclerosis relapsing patients.
    Lorenzi JC; Brum DG; Zanette DL; de Paula Alves Souza A; Barbuzano FG; Dos Santos AC; Barreira AA; da Silva WA
    Int J Neurosci; 2012 Aug; 122(8):466-71. PubMed ID: 22463747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated and dysregulated bone morphogenic proteins in immune cells of patients with relapsing-remitting multiple sclerosis.
    Mausner-Fainberg K; Urshansky N; Regev K; Auriel E; Karni A
    J Neuroimmunol; 2013 Nov; 264(1-2):91-9. PubMed ID: 24080309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
    Blumenfeld S; Staun-Ram E; Miller A
    J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis.
    Quan C; Yu H; Qiao J; Xiao B; Zhao G; Wu Z; Li Z; Lu C
    Mult Scler; 2013 Mar; 19(3):289-98. PubMed ID: 22864301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levels of plasma sulfatides C18 : 0 and C24 : 1 correlate with disease status in relapsing-remitting multiple sclerosis.
    Moyano AL; Pituch K; Li G; van Breemen R; Mansson JE; Givogri MI
    J Neurochem; 2013 Dec; 127(5):600-4. PubMed ID: 23777394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterisation of lymphocyte subpopulations in infantile haemangioma.
    Tan EM; Itinteang T; Chudakova DA; Dunne JC; Marsh R; Brasch HD; Davis PF; Tan ST
    J Clin Pathol; 2015 Oct; 68(10):812-8. PubMed ID: 26067666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls.
    Haegele KF; Stueckle CA; Malin JP; Sindern E
    J Neuroimmunol; 2007 Feb; 183(1-2):168-74. PubMed ID: 17084910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
    Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
    Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis.
    Nissimov N; Hajiyeva Z; Torke S; Grondey K; Brück W; Häusser-Kinzel S; Weber MS
    Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25690-25699. PubMed ID: 32999069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients.
    Frisullo G; Nociti V; Iorio R; Plantone D; Patanella AK; Tonali PA; Batocchi AP
    Hum Immunol; 2010 May; 71(5):437-41. PubMed ID: 20138197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.
    Li R; Rezk A; Ghadiri M; Luessi F; Zipp F; Li H; Giacomini PS; Antel J; Bar-Or A
    J Immunol; 2017 Jan; 198(2):691-698. PubMed ID: 27974457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.
    Zafranskaya M; Oschmann P; Engel R; Weishaupt A; van Noort JM; Jomaa H; Eberl M
    Immunology; 2007 May; 121(1):29-39. PubMed ID: 17239199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of interferon-beta on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-beta treatment in patients with multiple sclerosis.
    Wiesemann E; Deb M; Trebst C; Hemmer B; Stangel M; Windhagen A
    Mult Scler; 2008 Mar; 14(2):166-76. PubMed ID: 17942524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.